Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin.,International Journal of Hyperthermia

当前位置： X-MOL 学术 › Int. J. Hyperth. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin.
International Journal of Hyperthermia ( IF 3.1 ) Pub Date : 2020-07-20 , DOI: 10.1080/02656736.2020.1795277
N Laplace _{1,

2} , V Kepenekian _{1,

2} , A Friggeri _{3,

4} , O Vassal _{3,

4} , F Ranchon _{2,

5} , C Rioufol _{2,

5} , W Gertych _{2,

6} , L Villeneuve _{2,

7} , O Glehen _{1,

2} , N Bakrin _{1,

2}

Affiliation

Abstract

Background

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to provide benefits in the management of peritoneal metastasis. Cisplatin (CDDP) is one of the most frequently used drugs for peritoneal infusion. A major restriction is that CDDP causes renal toxicity and acute renal failure, sometimes leading to chronic renal failure. The aim of the present study was to assess the impact of sodium thiosulfate (ST) in preventing renal impairment (RI) following HIPEC with CDDP.

Methods

This prospective study assessed the RI rates for all patients who underwent HIPEC with CDDP during two successive periods: without ST (nST Period; from November 2016 to September 2017) and with ST (ST Period; from October 2017 to March 2018). During the ST Period, patients received an ST infusion at 9 mg/m² prior to HIPEC and at 12 mg/m² at the end of the procedure. RI was defined by postoperative serum creatinine >1.6 times elevation of baseline value. The impact of ST treatment was evaluated by comparison of the RI rates between the two periods.

Results

During ST Period, none of 38 patients (0%) developed RI versus 11/35 patients (31.4%) during the nST Period (p < .005); 2 of whom required definitive hemodialysis. Baseline characteristics, background circumstances, indications and laboratory parameters before HIPEC were comparable between the two groups, as well as CDDP dose use during HIPEC.

Conclusion

ST appears to be an effective drug for the prevention of the renal toxicity of CDDP used for HIPEC and should be used for all such procedures.

中文翻译：

顺铂进行高温腹膜内化疗（HIPEC）后，硫代硫酸钠可防止肾脏疾病。

摘要

背景

细胞减少术联合高温腹膜内化疗（HIPEC）已显示出可在腹膜转移管理中提供益处。顺铂（CDDP）是腹膜灌注最常用的药物之一。一个主要的限制是CDDP会引起肾毒性和急性肾衰竭，有时会导致慢性肾衰竭。本研究的目的是评估使用CDDP进行HIPEC后，硫代硫酸钠（ST）在预防肾功能不全（RI）中的作用。

方法

这项前瞻性研究评估了连续两个时期接受CDIP的HIPEC的所有患者的RI率：无ST（nST期; 2016年11月至2017年9月）和有ST（ST期; 2017年10月至2018年3月）。在ST期，患者在HIPEC之前接受9 mg / m ²的ST输注，而在手术结束时接受12 mg / m ²的ST输注。RI定义为术后血清肌酐>基线值升高1.6倍。通过比较两个时期的RI率来评估ST治疗的影响。